Results 101 to 110 of about 757,481 (306)

An Innovative Disease‐Drug‐Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate

Clinical and Translational Science, 2020
As with other psychiatric disorders, development of drugs to treat binge‐eating disorder (BED) has been hampered by high placebo response and dropout rates in randomized controlled trials (RCTs).
Shamir N. Kalaria, Susan L. McElroy, Jogarao Gobburu, Mathangi Gopalakrishnan   +3 more
doaj   +1 more source

Supplementary Figure 1 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

, 2023
<p>Supplementary Figure 1. Study flowchart</p>
Stan B. Kaye, Jaap Verweij, Josep Tabernero, Jean Charles Soria, Richard H. Wilson, Ruth Plummer, Jeffrey Evans, Emile Voest, Nicolas Penel, Jan H.M. Schellens, Silvia Marsoni, Patrick Schöffski, Andre T. Brunetto, Elisa Gallerani, Gianluca Del Conte, Rafael Morales-Barrera, Philippe A. Cassier, Carlos Gomez-Roca, David Olmos, Victor Moreno García   +19 more
openaire   +1 more source

Quantitative cross-species extrapolation between humans and fish: The case of the anti-depressant fluoxetine [PDF]

, 2014
This article has been made available through the Brunel Open Access Publishing Fund.Fish are an important model for the pharmacological and toxicological characterization of human pharmaceuticals in drug discovery, drug safety assessment and ...
ABA Boxall, AC Altamura, AC Johnson, Anna de Polo, BJ Ring, C Charlier, C Hiemke, C Lillesaar, C Maximino, CA LaLone, CB Eap, D Baldwin, D Kokel, DB Huggett, DJ Caldwell, DS Baldwin, ED Levin, EJ Perkins, FM McRobb, G Jannuzzi, GG Gould, Grace H. Panter, GT Ankley, J Cachat, J Klooster, J Kristensen, J Lundmark, J Rihel, J Rihel, JA Mennigen, JD Amsterdam, JG Kohlert, Jodi Pawluski, John P. Sumpter, JP Berninger, JP Seiler, JP Sumpter, JP Sumpter, JT Pittman, JV Goldstone, K Kuemmerer, KD Oakes, L Bjerkenstedt, L Fjordside, L Gunnarsson, L Ibrahim, L Margiotta-Casaluci, LD Ellis, Luigi Margiotta-Casaluci, M Rand-Weaver, M Schulz, M Sundvik, M Wolman, MA Lopez-Patino, Mariann Rand-Weaver, Matthew J. Winter, MC Celander, MG Scordo, MJ Airhart, MJ Owens, MJ Winter, MS Lipsky, MW Kelly, PD Anderson, RF Bergstrom, RJ Egan, Rob I. Cumming, RY Wong, SC Baraban, SC Dulawa, SH Preskorn, SH Preskorn, Stewart F. Owen, TJ Runnalls, TR Norman, TW Valenti Jr, TW Valenti Jr, WJAJ Smeets, YH Zhang, YJ Kim, Z Bencan   +80 more
core   +3 more sources

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source

The 90% minimum effective volume and concentration of lidocaine for ultrasound-guided stellate ganglion blocks in adults: a biased-coin design, up-and-down sequential allocation trial [PDF]

Korean Journal of Anesthesiology
Background As ultrasound imaging technology matured, stellate ganglion blocks (SGBs) have become increasingly precise and safe, and their use in clinical practice has become widespread. However, the 90% minimum effective volume (MEV90) and concentration (
Shujun Sun, Qinghua Yin, Jiwei Shen, Yang Lv, Long Li, Zhangyan Mao, Yun Lin, Xiangdong Chen, Dong Yang   +8 more
doaj   +1 more source

Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships

Frontiers in Pharmacology
Plasma drug concentrations have historically played a central role in pharmacology, serving as a measurable intermediary between administered dose and clinical response. This model, linking Dose, Concentration and Effect, underpins therapeutic drug monitoring, pharmacokinetic/pharmacodynamic (PK/PD) modeling, and regulatory evaluation.
Nicolas Simon, Katharina von Fabeck
openaire   +3 more sources

Supplementary table 1 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

, 2023
<p>Supplementary table 1. Main characteristics of patients receiving different dose levels</p>
Stan B. Kaye, Jaap Verweij, Josep Tabernero, Jean Charles Soria, Richard H. Wilson, Ruth Plummer, Jeffrey Evans, Emile Voest, Nicolas Penel, Jan H.M. Schellens, Silvia Marsoni, Patrick Schöffski, Andre T. Brunetto, Elisa Gallerani, Gianluca Del Conte, Rafael Morales-Barrera, Philippe A. Cassier, Carlos Gomez-Roca, David Olmos, Victor Moreno García   +19 more
openaire   +1 more source

Failure of Intravenous Morphine to Serve as an Effective Instrumental Reinforcer in Dopamine D2 Receptor Knock-Out Mice [PDF]

, 2002
The rewarding effects of opiates are thought to be mediated through dopaminergic mechanisms in the ventral tegmental area, dopamine-independent mechanisms in the nucleus accumbens, or both. The purpose of the present study was to explore the contribution
Elmer, Greg I., Grandy, David K., Low, Malcolm J., Pieper, Jeanne O., Rubinstein, Marcelo, Wise, Roy A.   +5 more
core   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source